ELI LILLY AND COMPANY

NYSE: LLY (Eli Lilly and Company)

Last update: 13 hours ago

895.35

10.15 (1.15%)

  • 1D 1.15%
  • 5D 7.95%
  • 1M 11.19%
  • 6M 9.33%
  • YTD 15.07%
  • 1Y 15.27%
  • 5Y 482.80%
Previous Close 885.20
Open 888.20
Volume 2,327,490
Avg. Volume (3M) 3,689,068
Market Cap 804,014,391,296
Price / Earnings (TTM) 76.66
Price / Earnings (Forward) 36.76
Price / Sales 16.61
Price / Book 52.34
52 Weeks Range
677.09 (-24%) — 972.53 (8%)
Earnings Date 1 May 2025
TTM Dividend Yield 0.60%
Profit Margin 23.51%
Operating Margin (TTM) 42.84%
Diluted EPS (TTM) 11.68
Quarterly Revenue Growth (YOY) 44.70%
Quarterly Earnings Growth (YOY) 101.40%
Total Debt/Equity (MRQ) 244.62%
Current Ratio (MRQ) 1.15
Operating Cash Flow (TTM) 8.82 B
Levered Free Cash Flow (TTM) 1.32 B
Return on Assets (TTM) 15.33%
Return on Equity (TTM) 84.26%

Market Trend

Short Term Medium Term
Industry Drug Manufacturers - General (US) Bearish Bullish
Drug Manufacturers - General (Global) Bearish Bullish
Stock Eli Lilly and Company Bearish Bullish

AIStockmoo Score

1.9
Analyst Consensus -0.5
Insider Activity 1.5
Price Volatility 2.0
Technical Moving Averages 2.5
Technical Oscillators 4.0
Average 1.90

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
LLY 804 B 0.60% 76.66 52.34
NVO 261 B 2.77% 16.90 13.27
MRK 213 B 3.73% 12.31 4.52
NVS 212 B 3.49% 18.03 4.97
JNJ 376 B 3.17% 17.37 4.77
ABBV 311 B 3.64% 72.57 90.53

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Sector Healthcare
Industry Drug Manufacturers - General
Investment Style Large Growth
% Held by Insiders 0.16%
% Held by Institutions 83.51%

Ownership

Name Date Shares Held
Lilly Endowment Inc 31 Mar 2025 96,016,978
Pnc Financial Services Group, Inc. 31 Dec 2024 51,303,099
Primecap Management Co/Ca/ 31 Dec 2024 16,756,654
State Farm Mutual Automobile Insurance Co 31 Dec 2024 12,646,138
52 Weeks Range
677.09 (-24%) — 972.53 (8%)
Price Target Range
700.00 (-21%) — 1,124.00 (-99%)
High 1,124.00 (Morgan Stanley, 25.54%) Buy
Median 975.00 (8.90%)
Low 700.00 (HSBC, -21.82%) Sell
Average 964.71 (7.75%)
Total 6 Buy, 1 Sell
Avg. Price @ Call 811.33
Firm Date Target Price Call Price @ Call
HSBC 28 Apr 2025 700.00 (-21.82%) Sell 877.29
Cantor Fitzgerald 22 Apr 2025 975.00 (8.90%) Buy 827.54
Guggenheim 14 Apr 2025 928.00 (3.65%) Buy 754.35
Morgan Stanley 09 Apr 2025 1,124.00 (25.54%) Buy 753.71
Goldman Sachs 08 Apr 2025 888.00 (-0.82%) Buy 726.24
Wells Fargo 05 Mar 2025 1,100.00 (22.86%) Buy 929.72
Truist Securities 03 Feb 2025 1,038.00 (15.93%) Buy 810.43
Name Avg. Buy ($) Avg. Sell ($) Net Quantity Net Value ($)
ALVAREZ RALPH 818.02 - 14 11,452
FYRWALD J ERIK 818.02 - 12 9,816
HEDLEY MARY LYNNE 818.02 - 12 9,816
LUCIANO JUAN R 818.02 - 18 14,724
SULZBERGER GABRIELLE 818.02 - 6 4,908
Aggregate Net Quantity 62
Aggregate Net Value ($) 50,717
Aggregate Avg. Buy ($) 818.02
Aggregate Avg. Sell ($) -
Name Holder Date Type Quantity Price Value ($)
ALVAREZ RALPH Director 21 Apr 2025 Acquired (+) 14 818.02 11,452
FYRWALD J ERIK Director 21 Apr 2025 Acquired (+) 12 818.02 9,816
HEDLEY MARY LYNNE Director 21 Apr 2025 Acquired (+) 12 818.02 9,816
LUCIANO JUAN R Director 21 Apr 2025 Acquired (+) 18 818.02 14,724
SULZBERGER GABRIELLE Director 21 Apr 2025 Acquired (+) 6 818.02 4,908
  • 3M
Date Type Details
29 Apr 2025 Announcement Cardiol Therapeutics Nominates Dr. Timothy Garnett to Its Board of Directors
29 Apr 2025 CNBC Novo Nordisk opens weight loss drug Wegovy to telehealth; Hims & Hers shares rocket 23%
28 Apr 2025 Announcement Scribe Achieves Milestone for In Vivo Program in Collaboration with Prevail Therapeutics, a part of Lilly’s Gene Therapy Division, and Announces ASGCT Joint Presentation on Self-Inactivating AAV Technology for Neurological and Neuromuscular Disorders
25 Apr 2025 CNBC Novo Nordisk scores major legal win that bars many compounded versions of Wegovy, Ozempic
24 Apr 2025 CNBC Corporate America shelled out millions for Trump's inauguration. Now he's upending many of their businesses
23 Apr 2025 CNBC Eli Lilly sues four telehealth sites selling compounded Zepbound, Mounjaro
17 Apr 2025 Announcement Lilly's oral GLP-1, orforglipron, demonstrated statistically significant efficacy results and a safety profile consistent with injectable GLP-1 medicines in successful Phase 3 trial
17 Apr 2025 CNBC Eli Lilly’s weight loss pill succeeds in first late-stage trial on diabetes patients; shares jump 14%
17 Apr 2025 Announcement Lilly confirms date and conference call for first-quarter 2025 financial results announcement
14 Apr 2025 CNBC Pfizer scraps daily weight loss pill after liver injury in one patient
11 Apr 2025 CNBC Trump's pharmaceutical tariffs could raise costs for patients, worsen drug shortages
09 Apr 2025 CNBC Pharmaceutical stocks rise as Trump pauses tariffs but not for China
01 Apr 2025 CNBC Eli Lilly sues two pharmacies making copycat Zepbound, Mounjaro
30 Mar 2025 Announcement Lilly's lepodisiran reduced levels of genetically inherited heart disease risk factor, lipoprotein(a), by nearly 94% from baseline at the highest tested dose in adults with elevated levels
29 Mar 2025 CNBC Novo Nordisk's diabetes pill slashes risk of cardiovascular complications by 14% after four years
27 Mar 2025 Announcement LillyDirect platform expands to facilitate access to Alzheimer's disease care
26 Mar 2025 Announcement Direxion Expands Single Stock Leveraged & Inverse ETF Lineup for Exposure to Eli Lilly & Palo Alto Networks
25 Mar 2025 Announcement Lilly announces details of presentations at 2025 American Association for Cancer Research (AACR) Annual Meeting
25 Mar 2025 Announcement Organovo Announces Close of the Sale of FXR Program to Eli Lilly and Company
24 Mar 2025 CNBC Eli Lilly will soon release key data on its weight loss pill. Here's why it could be a game-changer
22 Mar 2025 CNBC Zepbound copycats remain online despite FDA ban
18 Mar 2025 Announcement Lexarias' DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly's Injectable Zepbound
08 Mar 2025 Announcement Lilly's baricitinib delivered high rates of hair regrowth for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS study
07 Mar 2025 Announcement Lilly's EBGLYSS® (lebrikizumab-lbkz) single monthly maintenance injection achieved completely clear skin at three years in half of patients with moderate-to-severe atopic dermatitis
05 Mar 2025 CNBC Amgen starts two critical late-stage trials for weight loss drug MariTide
05 Mar 2025 CNBC Novo Nordisk offers Wegovy for less than half the price through new direct-to-consumer pharmacy
28 Feb 2025 Announcement Lilly to participate in Leerink Partners Global Healthcare Conference
28 Feb 2025 Announcement Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with relapsed or refractory chronic lymphocytic leukemia (CLL) previously treated with a BTK inhibitor
26 Feb 2025 CNBC Eli Lilly plans at least $27 billion in new U.S. manufacturing investments
26 Feb 2025 Announcement Lilly plans to more than double U.S. manufacturing investment since 2020 exceeding $50 billion
25 Feb 2025 Announcement Lilly launches additional Zepbound vial doses and offers new savings for self-pay patients
25 Feb 2025 Announcement Organovo’s FXR Program, including FXR314, to Be Acquired by Eli Lilly and Company
25 Feb 2025 CNBC Eli Lilly is selling higher-dose vials of Zepbound at a lower price to boost weight loss drug access
21 Feb 2025 CNBC Shortage of Novo Nordisk's Wegovy and Ozempic drugs is resolved, FDA says
20 Feb 2025 CNBC From pills to new uses, here's what Eli Lilly’s top scientist sees as the future of weight loss drugs
20 Feb 2025 CNBC Eli Lilly aims to invest in 'big problems hiding in plain sight' using obesity windfall 
18 Feb 2025 Announcement Lilly to participate in TD Cowen's 45th Annual Health Care Conference
07 Feb 2025 Announcement Most patients on Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease achieved sustained clinical remission and endoscopic response at two years
06 Feb 2025 Announcement Lilly reports full Q4 2024 financial results and provides 2025 guidance
06 Feb 2025 CNBC Eli Lilly to release late-stage data on next-generation weight loss drug retatrutide in 2025, earlier than expected
06 Feb 2025 CNBC Eli Lilly beats on earnings even as weight loss, diabetes drug sales fall short
05 Feb 2025 CNBC Novo Nordisk CEO says he's confident about Wegovy supply, next-generation weight loss drugs
Show more
TTM Dividend Yield 0.60%
5Y Average Dividend Yield 1.10%
Payout Ratio 44.41%
Expected Next Dividend Payment Sep 2025
Ex Date Announcement Date Payment Date Details
14 Feb 2025 09 Dec 2024 10 Mar 2025 1.5 Cash
15 Nov 2024 28 Oct 2024 10 Dec 2024 1.3 Cash
15 Aug 2024 24 Jun 2024 10 Sep 2024 1.3 Cash
15 May 2024 06 May 2024 10 Jun 2024 1.3 Cash
14 Feb 2024 08 Dec 2023 08 Mar 2024 1.3 Cash
14 Nov 2023 01 Nov 2023 08 Dec 2023 1.13 Cash
14 Aug 2023 26 Jun 2023 08 Sep 2023 1.13 Cash
12 May 2023 01 May 2023 09 Jun 2023 1.13 Cash
14 Feb 2023 12 Dec 2022 10 Mar 2023 1.13 Cash
14 Nov 2022 17 Oct 2022 09 Dec 2022 0.98 Cash
12 Aug 2022 27 Jun 2022 09 Sep 2022 0.98 Cash
13 May 2022 02 May 2022 10 Jun 2022 0.98 Cash
14 Feb 2022 13 Dec 2021 10 Mar 2022 0.98 Cash
12 Nov 2021 18 Oct 2021 10 Dec 2021 0.85 Cash
12 Aug 2021 29 Jun 2021 10 Sep 2021 0.85 Cash
13 May 2021 03 May 2021 10 Jun 2021 0.85 Cash
11 Feb 2021 14 Dec 2020 10 Mar 2021 0.85 Cash
12 Nov 2020 19 Oct 2020 10 Dec 2020 0.74 Cash
13 Aug 2020 15 Jul 2020 10 Sep 2020 0.74 Cash
14 May 2020 04 May 2020 10 Jun 2020 0.74 Cash
13 Feb 2020 16 Dec 2019 10 Mar 2020 0.74 Cash
14 Nov 2019 22 Oct 2019 10 Dec 2019 0.645 Cash
14 Aug 2019 20 Jun 2019 10 Sep 2019 0.645 Cash
16 May 2019 07 May 2019 10 Jun 2019 0.645 Cash
14 Feb 2019 19 Dec 2018 08 Mar 2019 0.645 Cash
14 Nov 2018 16 Oct 2018 10 Dec 2018 0.5625 Cash
14 Aug 2018 19 Jun 2018 10 Sep 2018 0.5625 Cash
16 May 2018 07 May 2018 08 Jun 2018 0.5625 Cash
14 Feb 2018 11 Dec 2017 09 Mar 2018 0.5625 Cash
14 Nov 2017 16 Oct 2017 08 Dec 2017 0.52 Cash
11 Aug 2017 19 Jun 2017 08 Sep 2017 0.52 Cash
11 May 2017 01 May 2017 09 Jun 2017 0.52 Cash
13 Feb 2017 12 Dec 2016 10 Mar 2017 0.52 Cash
10 Nov 2016 17 Oct 2016 09 Dec 2016 0.51 Cash
11 Aug 2016 20 Jun 2016 09 Sep 2016 0.51 Cash
11 May 2016 02 May 2016 10 Jun 2016 0.51 Cash
10 Feb 2016 08 Dec 2015 10 Mar 2016 0.51 Cash
10 Nov 2015 19 Oct 2015 10 Dec 2015 0.5 Cash
12 Aug 2015 15 Jun 2015 10 Sep 2015 0.5 Cash
14 May 2015 04 May 2015 10 Jun 2015 0.5 Cash
11 Feb 2015 15 Dec 2014 10 Mar 2015 0.5 Cash
12 Nov 2014 20 Oct 2014 10 Dec 2014 0.49 Cash
13 Aug 2014 16 Jun 2014 10 Sep 2014 0.49 Cash
13 May 2014 05 May 2014 10 Jun 2014 0.49 Cash
12 Feb 2014 16 Dec 2013 10 Mar 2014 0.49 Cash
13 Nov 2013 21 Oct 2013 10 Dec 2013 0.49 Cash
13 Aug 2013 18 Jun 2013 10 Sep 2013 0.49 Cash
14 May 2013 03 May 2013 10 Jun 2013 0.49 Cash
13 Feb 2013 17 Dec 2012 08 Mar 2013 0.49 Cash
13 Nov 2012 15 Oct 2012 10 Dec 2012 0.49 Cash
13 Aug 2012 19 Jun 2012 10 Sep 2012 0.49 Cash
13 Feb 2012 12 Dec 2011 09 Mar 2012 0.49 Cash
10 Nov 2011 17 Oct 2011 09 Dec 2011 0.49 Cash
11 Aug 2011 20 Jun 2011 09 Sep 2011 0.49 Cash
11 May 2011 18 Apr 2011 10 Jun 2011 0.49 Cash
11 Feb 2011 13 Dec 2010 10 Mar 2011 0.49 Cash
10 Nov 2010 18 Oct 2010 10 Dec 2010 0.49 Cash
11 Aug 2010 21 Jun 2010 10 Sep 2010 0.49 Cash
12 May 2010 19 Apr 2010 10 Jun 2010 0.49 Cash
10 Feb 2010 14 Dec 2009 10 Mar 2010 0.49 Cash
10 Nov 2009 19 Oct 2009 10 Dec 2009 0.49 Cash
12 Aug 2009 22 Jun 2009 10 Sep 2009 0.49 Cash
13 May 2009 20 Apr 2009 10 Jun 2009 0.49 Cash
11 Feb 2009 15 Dec 2008 10 Mar 2009 0.49 Cash
12 Nov 2008 20 Oct 2008 10 Dec 2008 0.47 Cash
13 Aug 2008 20 Jun 2008 10 Sep 2008 0.47 Cash
13 Feb 2008 17 Dec 2007 10 Mar 2008 0.47 Cash
13 Nov 2007 15 Oct 2007 10 Dec 2007 0.425 Cash
13 Aug 2007 21 Jun 2007 10 Sep 2007 0.425 Cash
11 May 2007 16 Apr 2007 08 Jun 2007 0.425 Cash
13 Feb 2007 18 Dec 2006 09 Mar 2007 0.425 Cash
13 Nov 2006 16 Oct 2006 08 Dec 2006 0.4 Cash
11 Aug 2006 26 Jun 2006 08 Sep 2006 0.4 Cash
11 May 2006 24 Apr 2006 09 Jun 2006 0.4 Cash
13 Feb 2006 19 Dec 2005 10 Mar 2006 0.4 Cash
10 Nov 2005 17 Oct 2005 09 Dec 2005 0.38 Cash
11 Aug 2005 24 Jun 2005 09 Sep 2005 0.38 Cash
11 May 2005 18 Apr 2005 10 Jun 2005 0.38 Cash
11 Feb 2005 20 Dec 2004 10 Mar 2005 0.38 Cash
10 Nov 2004 18 Oct 2004 10 Dec 2004 0.355 Cash
11 Aug 2004 28 Jun 2004 10 Sep 2004 0.355 Cash
12 May 2004 19 Apr 2004 10 Jun 2004 0.355 Cash
11 Feb 2004 15 Dec 2003 10 Mar 2004 0.355 Cash
12 Nov 2003 20 Oct 2003 10 Dec 2003 0.335 Cash
13 Aug 2003 23 Jun 2003 10 Sep 2003 0.335 Cash
13 May 2003 28 Apr 2003 10 Jun 2003 0.335 Cash
12 Feb 2003 16 Dec 2002 10 Mar 2003 0.335 Cash
13 Nov 2002 21 Oct 2002 10 Dec 2002 0.31 Cash
13 Aug 2002 24 Jun 2002 10 Sep 2002 0.31 Cash
13 May 2002 15 Apr 2002 10 Jun 2002 0.31 Cash
13 Feb 2002 17 Dec 2001 08 Mar 2002 0.31 Cash
13 Nov 2001 15 Oct 2001 10 Dec 2001 0.28 Cash
13 Aug 2001 25 Jun 2001 10 Sep 2001 0.28 Cash
11 May 2001 16 Apr 2001 11 Jun 2001 0.28 Cash
13 Feb 2001 18 Dec 2000 09 Mar 2001 0.28 Cash
13 Nov 2000 16 Oct 2000 11 Dec 2000 0.26 Cash
11 Aug 2000 26 Jun 2000 11 Sep 2000 0.26 Cash
11 May 2000 17 Apr 2000 09 Jun 2000 0.26 Cash
11 Feb 2000 20 Dec 1999 10 Mar 2000 0.26 Cash
10 Nov 1999 18 Oct 1999 10 Dec 1999 0.23 Cash
11 Aug 1999 19 Jul 1999 10 Sep 1999 0.23 Cash
12 May 1999 19 Apr 1999 10 Jun 1999 0.23 Cash
10 Feb 1999 21 Dec 1998 10 Mar 1999 0.23 Cash
10 Nov 1998 20 Oct 1998 10 Dec 1998 0.2 Cash
12 Aug 1998 20 Jul 1998 10 Sep 1998 0.2 Cash
13 May 1998 20 Apr 1998 10 Jun 1998 0.2 Cash
11 Feb 1998 15 Dec 1997 10 Mar 1998 0.2 Cash
12 Nov 1997 15 Sep 1997 10 Dec 1997 0.2 Cash
13 Aug 1997 21 Jul 1997 10 Sep 1997 0.36 Cash
13 May 1997 21 Apr 1997 10 Jun 1997 0.36 Cash
12 Feb 1997 16 Dec 1996 10 Mar 1997 0.36 Cash
13 Nov 1996 21 Oct 1996 10 Dec 1996 0.3425 Cash
13 Aug 1996 15 Jul 1996 10 Sep 1996 0.3425 Cash
13 May 1996 15 Apr 1996 10 Jun 1996 0.3425 Cash
13 Feb 1996 18 Dec 1995 11 Mar 1996 0.3425 Cash
13 Nov 1995 17 Oct 1995 11 Dec 1995 0.685 Cash
11 Aug 1995 17 Jul 1995 11 Sep 1995 0.645 Cash
09 May 1995 17 Apr 1995 12 Jun 1995 0.645 Cash
Show more

Annual Dividend Yield

Year Annual Dividend ($) Frequency/Year Yield %
2025 1.50 1 0.17
2024 5.20 4 0.67
2023 4.52 4 0.78
2022 3.92 4 1.07
2021 3.40 4 1.23
2020 2.96 4 1.75
2019 2.58 4 1.96
2018 2.25 4 1.94
2017 2.08 4 2.46
2016 2.04 4 2.77
2015 2.00 4 2.37
2014 1.96 4 2.84
2013 1.96 4 3.84
2012 1.47 3 2.98
2011 1.96 4 4.72
2010 1.96 4 5.59
2009 1.96 4 5.49
2008 1.41 3 3.50
2007 1.70 4 3.18
2006 1.60 4 3.07
2005 1.52 4 2.69
2004 1.42 4 2.50
2003 1.34 4 1.91
2002 1.24 4 1.95
2001 1.12 4 1.43
2000 1.04 4 1.12
1999 0.920 4 1.38
1998 0.800 4 0.90
1997 1.28 4 1.84
1996 1.37 4 3.75
1995 1.98 3 7.02
Show more

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2025 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria